Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men. (EPEP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01715636 |
Recruitment Status
:
Completed
First Posted
: October 29, 2012
Last Update Posted
: January 12, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study aims to describe the safety, tolerability and adherence to the coformulated anti-HIV drug tenofovir-emtricitabine-rilpivirine (eviplera) when given to men who have sex with men (MSM) following an actual or potential sexual exposure to HIV. This biomedical intervention is known as nonoccupational post-exposure prophylaxis (NPEP). Patients receive NPEP if they meet the criteria outlined in the 2007 National Australian NPEP Guidelines. Three or two anti-HIV drugs are administered for 28-days depending on the severity of the the assessed HIV acquisition risk. In this study eviplera would constitute 3-drug NPEP. Tenofovir-emtricitabine (truvada) a component of eviplera has been used in NPEP at SVH since 2006.
This is a multi site, prospective, open-label, non-randomised trial. Participants will be MSM who present at the various recruitment sites requesting NPEP. Initially, 50 eligible participants will be assigned to receive eviplera 25mg once daily taken with food for 28-days according to established Australian guidelines for the use of 3-drug NPEP. There will be 7 visits over a 12-week period. Follow-up post NPEP is for 8 weeks. If an interim analysis demonstrates acceptable safety, it is proposed to seek ethics approval to increase the samples size to 100 patients to gain more accurate information on regimen completion rate and on-drug adherence.
The primary study objectives are:
- To describe the safety of 28 days of NPEP using co-formulated FTC-RPV-TDF
- To describe the tolerability of 28 days of NPEP using FTC-RPV-TDF
- To describe on-drug adherence and regimen completion rates of 28 days of NPEP using FTC-RPV-TDF
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men | Drug: Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Safety, Tolerability, and Adherence to Co-formulated Emtricitabine-rilpivirine-tenofovir Used as HIV Nonoccupational Post Exposure Prophylaxis in Men Who Have Sex With Men (EPEP) |
Study Start Date : | December 2012 |
Actual Primary Completion Date : | July 2014 |
Actual Study Completion Date : | July 2014 |

Arm | Intervention/treatment |
---|---|
Eviplera
Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg, one tablet, once daily, taken with food, for 28 days
|
Drug: Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg
Other Name: Eviplera
|
- To describe the safety of 28 days of nonoccupational post-exposure prophylaxis with Eviplera [ Time Frame: 28 days ]Objective AE and SAE data collection/grading utilising DAIDS data collection tool. Measurement of weight, electrolytes, urea, creatinine, eGFR, inorganic phosphate, calcium, liver function, glucose, amylase, lipase, creatine kinase, lactate
- To describe the tolerability of 28 days of nonoccupational post-exposure prophylaxis with Eviplera [ Time Frame: 28 days ]Subjective reporting of AEs with data collection/grading utilising DAIDS-AE
- on-drug adherence and regimen completion dates [ Time Frame: 28 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Man who has sex with men
- Age at least 18 years
- Eligible for 3-drug NPEP according to Australian guidelines for the use of 3-drug NPEP following an actual or potential sexual exposure to HIV or receptive anal intercourse with an unknown source
- Able to provide written, informed consent
-
Able to commit to the study visits
Exclusion Criteria:
- Non-sexual exposure
- Exposure occurring during sex between a man and a woman
- HIV infection diagnosed on day 1 serological testing including indeterminate serology consistent with possible primary HIV infection
- Use of any medication contraindicated with FTC-RPV-TDF
- Serum hepatic transaminase (alanine aminotransferase [ALT] greater than 5 times the upper limit of the normal range
- Serum estimated Glomerular Filtration Rate (eGFR) <60mL/min/ BSAc
- Current therapy for hepatitis B
- Day 1 serological evidence of chronic/active hepatitis B
- Previous NPEP containing FTC-RPV-TDF
- A patient with a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01715636
Australia, New South Wales | |
Sydney Sexual Heatlh Centre | |
Sydney, New South Wales, Australia, 2000 | |
St Vincents Hospital | |
Sydney, New South Wales, Australia, 2010 | |
Australia, Victoria | |
The Alfred Hospital | |
Melbourne, Victoria, Australia, 3004 | |
Melbourne Sexual Health Centre | |
Melbourne, Victoria, Australia, 3053 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Andrew Carr, Professor, St Vincent's Hospital |
ClinicalTrials.gov Identifier: | NCT01715636 History of Changes |
Other Study ID Numbers: |
1.0 dated 28 May 2012 Carr (IN-AU-264-0119) ( Other Grant/Funding Number: Gilead Sciences Pty Ltd ) |
First Posted: | October 29, 2012 Key Record Dates |
Last Update Posted: | January 12, 2015 |
Last Verified: | January 2015 |
Additional relevant MeSH terms:
Tenofovir Emtricitabine Rilpivirine Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors |
Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents |